α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial

Abstract

BackgroundHigh-grade gliomas including glioblastoma multiforme (GBM) are among the most malignant and aggressive of tumors, and have a very poor prognosis despite a temozolomide-based intensive treatment. Therefore, a novel therapeutic approach to controlling recurrence is needed. In the present study, we investigated the effect of activated dendritic cell (DC) (α-type-1 polarized DC)-based immunotherapy on high-grade glioma patients with the HLA-A2 or A24 genotype.MethodsNine patients with recurrent high-grade gliomas including 7 with GBMs who fulfilled eligibility criteria were enrolled into a phase I study of monocyte-derived DC-based immunotherapy. HLA-genotyping revealed 1 case of HLA-A*0201 and 8 cases of A*2402. Enriched monocytes obtained using OptiPrepTM from leukapheresis products on day1, were incubated with GM-CSF and IL-4 in a closed serum-free system, and activated on day6 with TNF-α, IL-1β, IFN-α, IFN-γ, and poly I/C. After pulsing with a cocktail of 5 synthetic peptides (WT-1, HER2, MAGE-A3, and MAGE-A1 or gp100) restricted to HLA-A2 or A24 and KLH, cells were cryopreserved until used. Thawed DCs were injected intradermally in the posterior neck at a dose per cohort of 1.0, 2.0 and 5.0× 107/body.ResultsThe frequency of CD14+ monocytes increased to 44.6% from 11.9% after gradient centrifugation. After a 7-day-incubation with cytokines, the mean percentage of DCs rated as lin-HLA-DR+ in patients was 56.2 ± 19.1%. Most DCs expressed high levels of maturation markers, co-stimulatory molecules and type-1 phenotype (CD11c+HLA-DR+) with a DC1/2 ratio of 35.6. The amount of IL-12 produced from activated DCs was 1025 ± 443 pg/ml per 105 cells. All 76 DC injections were well tolerated except for transient liver dysfunction with grade II. Six patients showed positive immunological responses to peptides in an ELISPOT assay, and positive skin tests to peptide-pulsed DC and KLH were recognized in 4 cases. The clinical response to DC injections was as follows :1 SD and 8 PD. Interestingly, the SD patient, given 24 DC injections, showed a long-term recurrence-free and immunological positive response period.ConclusionsThese results indicate peptide cocktail-treated activated α-type-1 DC-based immunotherapy to be a potential therapeutic tool against recurrent high-grade glioma with mainly HLA-A*2402.Trial registrationCurrent non-randomized investigational trial UMIN-CTR UMIN ID: 000000914.

A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy

“…Another immunotherapeutic intervention that has been used in clinical trials is dendritic cell vaccination [71,72]. In our previous work [19], dendritic cell vaccination monotherapy was found to have some anti-tumor effect, but, counterintuitively, increasing the number of dendritic cells beyond a certain point was counterproductive.…”

Antitumor dendritic cell–based vaccines: lessons from 20 years of clinical trials and future perspectives

“…The resulting DCs, termed aDC1s, efficiently secrete IL-12p70 and were shown to elicit more potent CTL responses than the standard maturated DCs. 102,[109][110][111] From our analysis, aDC1-based vaccines were tested in at least 8 clinical trials (Fig 2, B).…”

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors

“…DC-based vaccines involve the isolation of patient's peripheral blood monocytes coupled with in vitro differentiation to DCs with GM-CSF and IL-4 [20], followed by antigen pulsing, further maturation, and subsequent intra-dermal vaccination [37][38][39]. There are a wealth of DC-cell based GBM vaccine trials currently open or completed [20,51,45].…”